Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-101
- Development stage
- Phase 2
- Lead developer
- HOOKIPA Pharma
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**HB-101** is an investigational, bivalent prophylactic vaccine intended to prevent human cytomegalovirus infection, particularly in kidney-transplant recipients at risk of donor-derived CMV. Developed by HOOKIPA Pharma using its non-replicating Vaxwave arenavirus platform, it consists of two replication-deficient lymphocytic choriomeningitis virus vectors encoding human CMV glycoprotein B and phosphoprotein 65. The gB component is intended to elicit CMV-neutralizing antibodies, while pp65 is intended to induce CMV-specific cellular immune responses. HB-101 completed Phase 1 and Phase 2 clinical studies; following Phase 2 results, HOOKIPA stated that it would not continue investing in the program. ([hookipapharma.com](https://www.hookipapharma.com/fileadmin/user_upload/Hookipa_Pharma/News_Press_Releases/20181217_Hookipa_CMV_Phase_II_Trial.pdf))
- Brand names
- Vaxwave
- Other names
- VaxWave CMV vaccine
02
Targets
gB (Human cytomegalovirus glycoprotein B)pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on HB-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-101.